Personalized μ-transcranial alternating current stimulation improves online brain-computer interface control.

Objective: A motor imagery (MI)-based brain-computer interface (BCI) enables users to engage with external environments by capturing and decoding electroencephalography (EEG) signals associated with the imagined movement of specific limbs. Despite significant advancements in BCI technologies over the past 40 years, a notable challenge remains: many users lack BCI proficiency, unable to produce sufficiently distinct and reliable MI brain patterns, hence leading to low classification rates in their BCIs. The objective of this study is to enhance the online performance of MI-BCIs in a personalized, biomarker-driven approach using transcranial alternating current stimulation (tACS).

Preclinical evaluation of the efficacy and safety of AAV8-TNAP-D10 in Alpl-/- and AlplPrx1/Prx1 mouse models for the treatment of early and late-onset hypophosphatasia.

We previously documented successful resolution of skeletal and dental disease in the infantile and late-onset murine models of hypophosphatasia (HPP), with a single injection of an adeno-associated serotype 8 vector encoding mineral-targeted TNAP (AAV8-TNAP-D10). Here, we conducted dosing studies in both HPP mouse models. A single escalating dose from 4x108 up to 4x1010 (vg/b) was intramuscularly injected into 4-day-old Alpl-/- mice (an infantile HPP model) and a single dose from 4x106 up to 4x109 (vg/b) was administered to 8-week-old AlplPrx1/Prx1 mice (a late-onset HPP model).

Personalized whole-brain activity patterns predict human corticospinal tract activation in real-time.

Background: Transcranial magnetic stimulation (TMS) interventions could feasibly treat stroke-related motor impairments, but their effects are highly variable. Brain state-dependent TMS approaches are a promising solution to this problem, but inter-individual variation in lesion location and oscillatory dynamics can make translating them to the poststroke brain challenging. Personalized brain state-dependent approaches specifically designed to address these challenges are needed.

Variants in the AGBL5 gene are responsible for autosomal recessive Retinitis pigmentosa with hearing loss.

The AGBL5 gene encodes for the Cytoplasmic Carboxypeptidase 5 (CCP5), an α-tubulin deglutamylase that cleaves the γ-carboxyl-linked branching point of glutamylated tubulin. To date, pathogenic variants in AGBL5 have been associated only with isolated retinitis pigmentosa (RP). Hearing loss has not been reported in AGBL5-caused retinal disease.